Ostometa 4 mg/5 ml (IV Infusion)
4 mg vial: ৳ 5,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Zoledronic acid for hypercalcemia |
| Company | Techno drugs ltd |
Indications
- Hypercalcaemia of malignancy
- Bone metastases associated with solid tumours
- Osteolytic lesions associated with multiple myeloma
- Corticosteroid-induced osteoporosis
- Increase bone mass in men with osteoporosis
- Osteoporosis in postmenopausal women
- Paget's disease of bone
- Prophylaxis of postmenopausal osteoporosis
Pharmacology
- Belongs to the class of nitrogen-containing bisphosphonates
- Acts primarily on bone
- Inhibitor of osteoclast-mediated bone resorption
- High affinity for mineralized bone
- Anti-tumour activity
- Anti-angiogenic activity
- Anti-pain activity
- Cytostatic and pro-apoptotic activity on tumour cells
- No accumulation in plasma after multiple doses
Dosage
- Maximum recommended dose for hypercalcemia of malignancy is 4 mg
- Recommended dose for multiple myeloma and bone metastases is 4 mg every 3-4 weeks
Administration
- Must be diluted with 100 ml of calcium-free infusion solution
- Duration of infusion must not be less than 15 minutes
- Must not be mixed with calcium or other divalent cation-containing infusion solutions
Interaction
- Administered concomitantly with commonly used anticancer agents, diuretics, antibiotics, and analgesics without interactions
- Caution advised when administered with aminoglycosides or loop diuretics
Contraindications
- Hypersensitivity to the active substance or any bisphosphonates
- Severe renal impairment (Creatinine clearance <30 ml/min)
- Pregnancy and lactation
Side Effects
- Headache
- Nausea
- Anorexia
- Fatigue
- Osteonecrosis of jaw
- Anemia
- Bone pain
- Constipation
- Fever
- Vomiting
- Flu-like syndrome
- Hypocalcemia
- Myalgia
- Arthralgia
- Hypophosphataemia
Pregnancy & Lactation
- Contraindicated during pregnancy and lactation
- Not recommended for use in children and adolescents below 18 years of age
Precautions & Warnings
- Patients must be appropriately hydrated prior to administration
- Serum levels of calcium, phosphate, magnesium, potassium, and creatinine should be carefully monitored
- Careful renal function monitoring should be considered
Use in Special Populations
- Not recommended in patients with severe renal impairment
- Dose adjustment based on creatinine clearance
Overdose Effects
- May cause hypocalcemia, hypophosphatemia, and hypomagnesemia
- Correction by intravenous administration of relevant substances
Therapeutic Class
- Bisphosphonate preparations
Reconstitution
- Dilute required amount in 100 mL of NaCl 0.9% or dextrose 5%
Storage Conditions
- Store below 30°C prior to opening
- Protect from moisture and light
- Keep out of the reach and sight of children